BRISTOL-MYERS SQUIBB COMPANY Deferred Gain on Sale of Property
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Deferred Gain on Sale of Property of $40.00 million as of 2014-12-31, per its 10-Q filed 2015-10-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredGainOnSaleOfProperty · last filed 2015-10-27
- 2014-12-31: Deferred Gain on Sale of Property $40.00M.
| Period end | Deferred Gain on Sale of Property |
|---|---|
| 2014-12-31 | $40.00M 10-Q · filed 2015-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |